摘要
背景:由于目前使用的治疗剂的非特异性细胞毒活性,癌症化疗受到严重副作用的限制。为了尽量减少这些不必要的影响,已经采取了几种方法,依靠使用光来激活药物。由于光能够以非常高的时空分辨率传递,该技术是在其作用部位选择性激活细胞毒性药物并由此提高化疗的耐受性和安全性的有前景的策略。 目的:本综述总结了不同的光化学疗法的方法,并确定其挑战和机遇。 结果:根据各自的光疗指数和活化所需的波长对各篇论文进行总结和评估。首先描述了包括铂 - ,钌 - 和铑 - 配合物的光活化金属配合物的设计,合成和/或评价。接下来,报道了光学金属配合物和光敏有机化学治疗剂,具有广泛的细胞毒性机制。最后一部分包括用于癌症治疗的光敏药物的例子。 _一些设计,特别是金属络合物,由于其非常高的光治疗指数(> 1880)而突出,但是光响应性金属络合物和有机化学治疗剂的共同缺点是活化的不可逆性。然而,照片可切换的药物解决了这个挑战。尽管如此,紫外线对其激活的需求仍然限制了它们的应用。 结论:光敏化癌症化学疗法领域正在快速发展,已经包含了非常有前途的方法,其设计提供了高度的光治疗指数,并且还包括NIR或可见光活化的药物。
关键词: 光活化,癌症,化学疗法,光照,金属络合物,光药理学。
Current Medicinal Chemistry
Title:Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Volume: 24 Issue: 42
关键词: 光活化,癌症,化学疗法,光照,金属络合物,光药理学。
摘要: Background: Cancer chemotherapy is limited by severe side effects due to unspecific cytotoxic activity of currently used therapeutics. In order to minimize these unwanted effects, several approaches have been taken, relying on the use of light to activate drugs. As light can be delivered with a very high spatiotemporal resolution, this technique is a promising strategy to selectively activate cytotoxic drugs at their site of action and thus to improve the tolerability and safety of chemotherapy.
Objective: This review summarizes different approaches towards photoactivated chemotherapy and identifies its challenges and opportunities.
Results: The respective papers were summarized and evaluated in terms of their phototherapeutic indices and the wavelength needed for activation. First, the design, synthesis and/or evaluation of photoactivated metal complexes including platinum- , ruthenium-, and rhodium-complexes is described. Next, photocaged metal complexes and photoacaged organic chemotherapeutics are reported, with a wide range of cytotoxicity mechanisms. The final part includes, examples of photoswitchable drugs for cancer therapy.
Some designs, especially metal complexes, stand out due to their very high phototherapeutic index (> 1880) but the common drawback of light-responsive metal complexes and organic chemotherapeutics is the irreversibility of activation. Photoswitchable drugs, however, address this challenge. Nevertheless, the need of UV light for their activation still limits their application.
Conclusion: The field of photoactivated cancer chemotherapy is rapidly growing and already includes very promising approaches with designs providing high phototherapeutic indices and also NIR or visible light-activatable drugs.
Export Options
About this article
Cite this article as:
Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy, Current Medicinal Chemistry 2017; 24 (42) . https://dx.doi.org/10.2174/0929867323666160906103223
DOI https://dx.doi.org/10.2174/0929867323666160906103223 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design Intracellular Trafficking of MDR Transporters and Relevance of SNPs
Current Topics in Medicinal Chemistry A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro
Current Medicinal Chemistry Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety How does the Selection of Laboratory Mice Affect the Results of Physiological Distribution of Radiopharmaceuticals?
Current Radiopharmaceuticals The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism Antibody Fragment and Targeted Colorectal Cancer Therapy: A Global Systematic Review
Current Pharmaceutical Biotechnology Chemically Functionalized Carbon Nanotubes: Emerging Vectors for Cell Therapy
Mini-Reviews in Medicinal Chemistry Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine